Resolution Therapeutics

The company's primary focus is on developing treatments for end-stage liver disease (ESLD), a condition with limited therapeutic options beyond liver transplantation. Resolution Therapeutics engineers autologous macrophages, a type of immune cell, to enhance their natural anti-inflammatory and anti-fibrotic properties, thereby promoting organ regeneration. The business model centers on the discovery, development, and commercialization of these proprietary cell therapies. Its lead product candidate, RTX001, is an engineered macrophage therapy for patients with liver cirrhosis, aiming to prevent the need for transplants. In late 2024, the company initiated a Phase I/II clinical trial, named EMERALD, to assess the safety and efficacy of RTX001 in the UK and Spain.

Resolution Therapeutics is backed by Syncona Ltd, a healthcare investment company that led its £26.6 million Series A financing in 2020 and a £63.5 million Series B in 2024. These funds are allocated to advancing RTX001 through clinical trials, expanding the research pipeline to other fibrotic diseases like lung fibrosis, and enhancing manufacturing capabilities. The company is also exploring the development of an allogeneic, or "off-the-shelf," platform for its macrophage therapies through collaborations.